Strong revenue growth fails to shield India Inc margins in March quarter

Corporate India posted robust revenue increases during the March 2026 quarter. However, rising input costs and a weaker rupee pressured operating margins across many companies.

Sectors such as automobiles and banking recorded solid growth. In contrast, cement and oil companies encountered notable difficulties amid the same period.

Verwandte Artikel

Realistic illustration showing India's economic growth with cityscape and financial symbols amid global challenges.
Bild generiert von KI

Indiens Wirtschaft wächst 2025-26 trotz globaler Erschütterungen um 7,7 Prozent

Von KI berichtet Bild generiert von KI

Vorläufige BIP-Schätzungen, die am Freitag veröffentlicht wurden, zeigen ein Wachstum von 7,7 Prozent für 2025-26. Dieser Wert übertrifft die Prognose der Regierung vom Februar um 0,1 Prozentpunkte. Der Ausblick für 2026-27 deutet auf eine Verlangsamung hin.

Nifty 50 firms expect double-digit revenue growth for the June 2026 quarter but project only single-digit profit increases due to rising costs. Input cost inflation and higher crude prices are squeezing margins across sectors.

Von KI berichtet

India's listed brokers and exchanges posted strong results for the March quarter. Growth came from higher margin trading and increased market activity.

Gokaldas Exports achieved strong sequential growth in both revenue and profit for the March quarter. The company posted a 9% rise in revenue despite ongoing global trade disruptions and US tariff pressures.

Von KI berichtet

Tata Consultancy Services posted flat dollar revenue for the June quarter along with margin contraction. AI revenue grew but stayed a small share of total earnings. The company also paid out large dividends.

Nine BSE smallcap companies delivered standout performances in the March 2026 quarter, with net profits surging over 50% year-on-year and share prices rising 50% to 170% in the past year. Four of these stocks became multibaggers, more than doubling investor returns. Data from ACE Equity highlights the momentum amid mixed results from 168 reporting firms.

Von KI berichtet

Indian pharmaceutical companies Dr Reddy's and Cipla reported weaker results for the June quarter due to falling profits in the US market. Their domestic operations performed better and provided some offset. Analysts lowered earnings estimates for future years as a result.

 

 

 

Diese Website verwendet Cookies

Wir verwenden Cookies für Analysen, um unsere Website zu verbessern. Lesen Sie unsere Datenschutzrichtlinie für weitere Informationen.
Ablehnen